Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported open‑market sales of 139,951 shares of Common Stock, carried out on behalf of a living trust. The sales occurred at weighted average prices within ranges between $210.0564 and $250.0100 per share.
The filing states these transactions were executed automatically under a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2025. The shares are held through a living trust and several estate planning trusts, for which the reporting person disclaims beneficial ownership except for any pecuniary interest.
ALAB submitted a Form 144 disclosing proposed and recent sales of Common Stock by a selling holder. The filing lists restricted stock vesting under a registered plan with vesting date 05/15/2025 in amounts 5,081, 1,502, and 1,846 shares. It also records a sale by TATE 1997 LIVING TRUST of 49,665 shares on 05/14/2026 for $11,234,674.95.
Form 144 notice: proposed sale of Common Stock. The filing lists a proposed sale of 40,000 shares with an associated value of $8,623,200.00 and a filing date of 05/19/2026. The excerpt also reports prior 10b5-1 sales on 05/07/2026 totaling 280,000 shares (examples: 40,000; 200,000; 40,000) with proceeds shown in the filing.
The notice identifies the securities as Common stock and records the original acquisition date as 11/21/2017 by private acquisition from the issuer or an affiliate. The excerpt lists trustee names and addresses associated with the prior 10b5-1 sales. This filing is a regulatory notice of a proposed sale; timing and cash-flow recipients are set by the selling holder information in the filing.
ALAB - Form 144 notice of proposed sale of restricted/common shares. The filing lists 40,000 shares of Common stock to be sold under Rule 144 with an aggregate dollar amount of $8,623,200.00. The filing notes prior 10b5-1 sales during the past three months totaling 280,000 shares across named trusts with aggregate proceeds recorded.
The securities to be sold were acquired 11/21/2017 (private acquisition from issuer or affiliate). The filing date shown is 05/19/2026 and sales listed as effected on 05/07/2026 for the prior transactions.
ALAB affiliate submits Form 144 to sell 200,000 shares. The filing lists 200,000 shares of Common stock associated with a sale and includes a $43,116,000.00 figure and an outstanding share count of 171,407,939 as shown in the excerpt.
The filing also records prior 10b5-1 sales on 05/07/2026 of 40,000, 200,000, and 40,000 Common shares with corresponding reported proceeds. The filing identifies the trades as connected to trusts and notes a Private Acquisition from Issuer or an Affiliate dated 11/21/2017.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara acquired additional company stock through an employee purchase program. On May 14, 2026, he received 131 shares of common stock at $120.1815 per share under the 2024 Employee Stock Purchase Plan, bringing his direct holdings to 118,215 shares. The filing notes these plan purchases were exempt under Rule 16b-3(d) and Rule 16b-3(c).
ALAB submitted a Form 144 disclosure listing proposed resale of common stock and several previously issued restricted stock grants. The filing shows two reported open-market dispositions by Philip Mazzara of 10,000 shares each on 03/02/2026 and 04/01/2026, with proceeds of $1,174,740.60 and $1,077,662.85, respectively. The excerpt also lists restricted stock issuances dated 08/15/2024, 11/15/2023, 02/15/2024, 08/15/2023, and 05/15/2024 with individual share counts shown.
ALAB notice under Form 144 reports proposed sales tied to restricted stock vesting and multiple dispositions by Michael Truett. The filing lists vesting entries of 29,937, 12,020, 7,014, and 694 shares with vesting dates in 2024 and 2025. The filing also discloses sales by Michael Truett on 02/17/2026 of 4,250, 3,556, 2,281, 1,161, and 753 shares, each with accompanying dollar amounts reported.
Astera Labs, Inc. director and President/COO Gajendra Sanjay reported insider sales executed through estate-planning trusts. On May 7, 2026, trusts identified as "Trust 2" and "Trust 3" sold an aggregate of 49,361 shares of Common Stock in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
The reported weighted average sale prices span ranges disclosed in multiple footnotes, including transactions within bands such as $192.4400 to $193.4300 and up to higher ranges reflected in individual line items. Following these transactions, Sanjay continues to hold 1,531,301 shares directly, while the trusts still hold over 650,000 shares each. The filing states that the shares in Trust 2 and Trust 3 are owned directly by estate planning trusts, and Sanjay disclaims beneficial ownership except to the extent of any pecuniary interest.
Astera Labs, Inc. estate planning trusts reported sizeable planned share sales. On May 7, 2026, trusts associated with President and COO Gajendra Sanjay sold a total of 230,639 shares of Astera Labs common stock in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025. Individual blocks were sold at prices including $198.8237 and $213.49 per share. After these sales, one estate planning trust (Trust 1) reported holding 5,859,488 shares, while a second trust (Trust 2) reported holding 694,055 shares. The filing states that Sanjay disclaims beneficial ownership of these trust-held securities except to the extent of any pecuniary interest.